Search Results - "B Arnulf"

Decoding the activity of neuronal populations in macaque primary visual cortex by Graf, Arnulf B A, Kohn, Adam, Jazayeri, Mehrdad, Movshon, J Anthony

“…Graf et al . examine how information can be decoded from the pattern of population activity in primary visual cortex neurons. They find that the structure of…”
Get full text

Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients by Vignon, M, Javaugue, V, Alexander, M P, El-Karoui, K, Karras, A, Roos-Weil, D, Royer, B, Asli, B, Knebelmann, B, Touchard, G, Jaccard, A, Arnulf, B, Bridoux, F, Leung, N, Fermand, J P

“…We retrospectively reviewed 49 patients with light chain (LC) Fanconi syndrome (FS). Patients presented with chronic kidney disease (median estimated…”
Get full text

Nucleotide excision repair is a potential therapeutic target in multiple myeloma by Szalat, R, Samur, M K, Fulciniti, M, Lopez, M, Nanjappa, P, Cleynen, A, Wen, K, Kumar, S, Perini, T, Calkins, A S, Reznichenko, E, Chauhan, D, Tai, Y-T, Shammas, M A, Anderson, K C, Fermand, J-P, Arnulf, B, Avet-Loiseau, H, Lazaro, J-B, Munshi, N C

“…Despite the development of novel drugs, alkylating agents remain an important component of therapy in multiple myeloma (MM). DNA repair processes contribute…”
Get full text

Rituximab with alkylating agent in anti-myelin-associated glycoprotein neuropathy: A retrospective study of 26 cases by Elessa, D, Grosjean, V, Lozeron, P, Harel, S, Royer, B, Forgeard, N, Thèves, F, Talbot, A, Malphettes, M, Bengoufa, D, Kubis, N, Arnulf, B

Get full text

Brain–machine interface for eye movements by Graf, Arnulf B. A., Andersen, Richard A.

“…A number of studies in tetraplegic humans and healthy nonhuman primates (NHPs) have shown that neuronal activity from reach-related cortical areas can be used…”
Get full text

Plasma cell-directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema by Theves, F, Lahuna, C, Mahévas, T, Harel, S, Royer, B, Lemiale, V, Brignier, A, Parquet, N, Jachiet, M, Bouaziz, J-D, Elessa, D, Arnulf, B, Talbot, A

“…Scleromyxedema (SM) is a rare skin disorder related to monoclonal gammopathy. High dose intravenous immunoglobulins (HDIVIg) are usually used as a frontline…”
Get full text

French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM study from the DESCAR‐T registry by Ferment, B., Lambert, J., Caillot, D., Lafon, I., Karlin, L., Lazareth, A., Touzeau, C., Leleu, X., Moya, N., Harel, S., Perrot, A., Bories, P., Vincent, L., Lamure, S., Mohty, M., Malard, F., Manier, S., Yakoub‐Agha, I., Schiano De Colella, J.‐M., Brisou, G., Talbot, A., Decaux, O., Houot, R., Le Gouill, S., Bigot, N., Facon, T., Corre, J., Moreau, P., Arnulf, B.

“…Summary Idecabtagene vicleucel (ide‐cel), a chimeric antigen receptor T‐cell therapy targeting B‐cell maturation antigen (BCMA), received early access program…”
Get full text

Perioral skin thickening revealing AL amyloidosis by Billard, K., Arnulf, B., Kottler, D., Mirouse, A., Harel, S., Royer, B., Bagot, M., Jachiet, M., Bouaziz, J.D., Mahévas, T.

Get full text

Predicting oculomotor behaviour from correlated populations of posterior parietal neurons by Graf, Arnulf B. A., Andersen, Richard A.

“…Oculomotor function critically depends on how signals representing saccade direction and eye position are combined across neurons in the lateral intraparietal…”
Get full text

Clinical presentation, therapeutic approach and outcome of primary cutaneous marginal zone B‐cell lymphoma presenting as AL amyloidoma of the skin by Dangien, A., Beylot‐Barry, M., Battistella, M., Ram‐Wolff, C., Talbot, A., Rybojad, M., Vergier, B., Jachiet, M., Bouaziz, J.‐D., Arnulf, B., Bagot, M., Masson, A.

Get full text

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma by Leleu, X, Fouquet, G, Hebraud, B, Roussel, M, Caillot, D, Chrétien, M L, Arnulf, B, Szalat, R, Garderet, L, Benajiba, L, Pegourie, B, Regny, C, Royer, B, Caulier, A, Stoppa, A M, Garciaz, S, Touzeau, C, Chaleteix, C, Fermand, J P, Loiseau, H A, Facon, T, Attal, M, Moreau, P

Get full text

Coexisting cutaneous macroglobulinosis and scleredema of Buschke in a patient with a Waldenström Macroglobulinemia by Roupie, A.L., Battistella, M., Talbot, A., Jachiet, M., Bouaziz, J.D., Vignon‐Pennamen, M.D., Royer, B., Fermand, J.P., Arnulf, B., Harel, S.

Get full text

KIR3DL2 expression in patients with adult T‐cell lymphoma/leukaemia by Hurabielle, C., Leboeuf, C., Ram‐Wolff, C., Meignin, V., Rivet, J., Vignon‐Pennamen, M.‐D., Bonnafous, C., Sicard, H., Fite, C., Raffoux, E., Arnulf, B., Oksenhendler, E., Sicre de Fontbrune, F., Peffault de Latour, R., Socié, G., Bouaziz, J.‐D., Lebbé, C., Bensussan, A., Janin, A., Bagot, M., Battistella, M.

Get full text

Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma by ARNULF, B, LECOURT, S, FERMAND, J.-P, MAROLLEAU, J.-P, LARGHERO, J, SOULIER, J, TERNAUX, B, LACASSAGNE, M.-Noelle, CRINQUETTE, A, DESSOLY, J, SCIAINI, A.-K, BENBUNAN, M, CHOMIENNE, C

“…Multiple myeloma (MM) is a B-cell neoplasia caused by the proliferation of clonal plasma cells, primarily in the bone marrow (BM). The role of the BM…”
Get full text

EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN–DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES by A Nooka, A Lesokhin, M Mohty, R Niesvizky, C Maisel, B Arnulf, S Larson, A Varshavsky-Yanovsky, X Leleu, L Karlin, D Vesole, N Bahlis, CF Larrea, N Raje, E Leip, U Conte, M Elmeliegy, A Viqueira, V Blunk, S Manier

“…Introduction/Objectives: To evaluate the efficacy and safety of elranatamab in a pooled analysis of patients (pts) enrolled in MagnetisMM trials with relapsed…”
Get full text

ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY by M Mohty, M Tomasson, B Arnulf, N Bahlis, M Prince, R Niesvizky, P Rodrgue-Otero, J Martine-Lopez, G Koehne, Y Jethava, A Gabayan, D Stevens, A Nooka, N Raje, S Iida, E Leip, U Conte, A Czibere, A Viqueira, V Blunk, A Lesokhin

“…Introduction/Objectives: To report the findings of extended follow-up and biweekly administration of elranatamab monotherapy in patients (pts) with…”
Get full text

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma by Fouquet, G., Pegourie, B., Macro, M., Petillon, M.O., Karlin, L., Caillot, D., Roussel, M., Arnulf, B., Mathiot, C., Marit, G., Kolb, B., Stoppa, A.M., Brechiniac, S., Richez, V., Rodon, P., Banos, A., Wetterwald, M., Garderet, L., Royer, B., Hulin, C., Benbouker, L., Decaux, O., Escoffre-Barbe, M., Fermand, J.P., Attal, M., Avet-Loiseau, H., Moreau, P., Facon, T., Leleu, X.

“…The IFM2009-02 trial studied pomalidomide (4 mg daily, 21/28 versus 28/28) and dexamethasone in very advanced relapsed or refractory multiple myeloma (RRMM)…”
Get full text

P16 HEALTH‐RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT‐INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL by Facon, T., Plesner, T., Usmani, S., Kumar, S., Bahlis, N., Hulin, C., Orlowski, R., Nahi, H., Mollee, P., Ramasamy, K., Roussel, M., Jaccard, A., Delforge, M., Karlin, L., Arnulf, B., Chari, A., Pei, H., Gupta, N., Kaila, S., Matt, K., Gries, K., Carson, R., Borgsten, F., Weisel, K., Perrot, A.

Get full text

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE‐CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA‐3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL by Rodríguez‐Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A.K., Manier, S., Callander, N., Costa, L.J., Vij, R., Bahlis, N.J., Moreau, P., Solomon, S.R., Delforge, M., Berdeja, J., Truppel‐Hartmann, A., Yang, Z., Favre‐Kontula, L., Wu, F., Piasecki, J., Cook, M., Giralt, S.

Get full text

The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo by BONO, Camille, KARLIN, Lionel, ARNULF, Bertrand, HAREL, Stephanie, MOULY, Enguerran, LABAUME, Sylvaine, GALICIER, Lionel, APCHER, Sébastien, SAUVAGEON, Hélène, FERMAND, Jean-Paul, BORIES, Jean-Christophe

“…Multiple myeloma is characterized by the accumulation of tumor plasma cells in the bone marrow. Despite therapeutic improvements brought by proteasome…”
Get full text